Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology.

Marcotullio S, Ammassari A, Andreoni M, Antinori A, Bonora S, d'Arminio Monforte A, Di Perri G, Galli M, Gervasoni C, Iardino R, Ippolito G, Lo Caputo S, Nozza S, Perno CF, Rizzardini G, Lazzarin A.

New Microbiol. 2014 Apr;37(2):163-75. Epub 2014 Apr 1.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.

Naggie S, Hicks C.

J Antimicrob Chemother. 2010 Jun;65(6):1094-9. doi: 10.1093/jac/dkq130. Epub 2010 Apr 23. Review.

PMID:
20418273
4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
5.

The role of protease inhibitor therapy in children with HIV infection.

Gavin PJ, Yogev R.

Paediatr Drugs. 2002;4(9):581-607. Review.

PMID:
12175273
6.

[Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].

Brunner J, Seybold U, Gunsenheimer-Bartmeyer B, Hamouda O, Bogner JR; ClinSurv-Studiengemeinschaft (gleichwertiger Beitrag).

Dtsch Med Wochenschr. 2010 Jun;135(23):1166-70. doi: 10.1055/s-0030-1255124. Epub 2010 May 31. German.

PMID:
20514595
7.

HIV-1 protease inhibitors in development.

Rusconi S, La Seta Catamancio S.

Expert Opin Investig Drugs. 2002 Mar;11(3):387-95. Review.

PMID:
11866667
8.

Dual protease inhibitor therapy in the management of the HIV-1.

Yu K, Daar ES.

Expert Opin Pharmacother. 2000 Dec;1(7):1331-42. Review.

PMID:
11249468
9.

Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group.

J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927.

PMID:
20981785
10.

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.

von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Arch Intern Med. 2007 Sep 10;167(16):1782-90.

PMID:
17846398
11.

Recent developments of peptidomimetic HIV-1 protease inhibitors.

Qiu X, Liu ZP.

Curr Med Chem. 2011;18(29):4513-37. Review.

PMID:
21864279
12.

Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.

Tsuchiya K, Matsuoka-Aizawa S, Yasuoka A, Kikuchi Y, Tachikawa N, Genka I, Teruya K, Kimura S, Oka S.

J Clin Virol. 2003 Aug;27(3):252-62.

PMID:
12878089
13.

Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.

Gianotti N, Tambussi G, Boeri E, Lazzarin A.

J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):166-9.

PMID:
11501975
14.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

De Luca A, Hamers RL, Schapiro JM.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S63-9. doi: 10.1093/infdis/jit109. Review.

PMID:
23687291
15.

Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.

Pediatrics. 2005 Feb;115(2):e173-82. Epub 2005 Jan 3.

PMID:
15629958
16.
17.

Atazanavir: a novel HIV-1 protease inhibitor.

Piliero PJ.

Expert Opin Investig Drugs. 2002 Sep;11(9):1295-301. Review.

PMID:
12225250
18.

The great salvage therapy drug juggle.

Cadman J.

GMHC Treat Issues. 1998 Apr;12(4):1-6.

PMID:
11365398
19.

Predictors of virologic response to ritonavir-boosted protease inhibitors.

Marcelin AG, Flandre P, Peytavin G, Calvez V.

AIDS Rev. 2005 Oct-Dec;7(4):225-32. Review.

PMID:
16425962
20.

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2003 Oct;8(5):443-54.

PMID:
14640392

Supplemental Content

Support Center